Pfizer shares reach 52-week high amid recovery efforts

Pfizer shares have recently reached a 52-week high, marking progress in the company's attempt to emerge from a post-pandemic slump. Year to date, the stock has risen 20% while maintaining a forward dividend yield of approximately 5.8%.

The company is currently implementing cost-reduction programs, with management projecting potential savings of up to $6.7 billion through 2029. Financial performance has been bolstered by sales of products such as the blood thinner Eliquis and cancer treatments Padcev and Lorbrena, which have helped offset declining sales of COVID-19 related products.

Technical analysis suggests a potential bullish reversal pattern, specifically an inverted head and shoulders formation. Analysts note that a decisive close above the $30.89 neckline could signal a larger recovery trend, with technical targets reaching the $40 to $41 range.